IMPORTANCE Granuloma faciale (GF) is a rare, benign inflammatory dermatosis of unknown cause. Some reports have suggested that it could be part of the spectrum of IgG4-related sclerosing diseases. Granuloma faciale is characterized by single or multiple red-brown nodules, most frequently occurring on the face, and it can produce severe disfigurement. Treatment is difficult, and poor outcomes are often seen. Rituximab is a monoclonal antibody against CD-20 approved by the US Food and Drug Administration for treatment of some autoimmune and tumoral diseases.
G ranuloma faciale (GF) is a rare, benign inflammatory dermatosis of unknown cause, characterized by single or multiple red-brown or violaceous cutaneous nodules or plaques, most frequently occurring on the face. 1 It is considered a localized chronic fibrosing vasculitis, 1 and some reports have suggested that GF could be part of the spectrum of IgG4-related diseases (IgG4-RD). 2 Treatment is difficult, and poor outcomes are often seen. 3 Rituximab is a monoclonal antibody against CD-20 approved by the US Food and Drug Administration for treatment of some autoimmune and tumoral diseases. 4 Because good responses to rituximab have been reported in patients with cutaneous vasculitis 5 or
IgG4-RD, 6 we sought to evaluate intralesional rituximab in refractory GF.
Methods
Three patients with biopsy-proved GF that had been refractory to multiple therapies were treated with intralesional rituximab at the department of dermatology, Hospital Clínic de Barcelona, a tertiary referral Spanish hospital, between August 2015 and December 2017. The therapeutic committee of our institution approved the off-label use of this medication. All patients gave oral and written informed consent; there was no financial compensation. Doses of rituximab, 0.5 to 1 mL/cm 2 , with a concentration of 10 mg/mL, were indicated. We administered monthly injections during the first 6 months, and their frequency after that depended on clinical response. No other treatment was used. The patients were followed up both clinically and with high-resolution ultrasonography (Esaote MyLab Class C with 18-and 22-MHz probes) every 2 to 3 months.
Clinical response was evaluated by measuring the size and thickness of GF. We considered a reduction in the size and thickness of the tumor of more than 75% as a complete clinical response (CR), a reduction of 50% to 75% as a partial clinical response (PR), and reductions of less than 50% as an incomplete clinical response. Tumor thickness and vascularization were measured on ultrasonography evaluation. In 2 patients, peripheral blood B-cell counts were monitored at baseline and after 6 months of treatment, and in the third patient, after 12 months. Blood cell counts and metabolic panel results were checked at baseline and during follow-up. Adverse effects were monitored throughout the therapy. The 3 cases are summarized in the Table.
Report of Cases

Case 1
A man in his 30s presented with a 5-year history of a 4-cm, redbrown nodule on his right cheek. Two biopsies confirmed GF. Previous treatments included topical corticosteroids and tacrolimus, hydroxychloroquine, dapsone, and laser therapy with no clinical response. Intralesional rituximab was initiated, and thinning of the lesion was observed after the third month. Ultrasonography showed a reduction in both tumor thickness and vascularization. The peripheral B-cell count of 5% at baseline was 0 after 6 months of intralesional rituximab therapy. Intralesional rituximab was stopped after 7 months because the lesion showed only a PR.
In the following 2 months, the lesion expanded in size and thickness, and high-resolution ultrasonography showed an increase in vascularization. Intralesional rituximab was then reinitiated with a clear response in the following months. At the time of writing, the patient had completed 11 infiltrations with PR and was still receiving treatment. He was satisfied with the cosmetic result. Blood analyses results performed throughout this period have been within reference ranges. The only observed adverse effect has been moderate pain during infiltrations.
Case 2
A man in his 60s presented with a 12-year history of redbrown nodules in his ear ( Figure 1A ) and navel. Granuloma faciale was confirmed by several biopsies and showed dense lymphoplasmocytic inflammatory infiltrates. Immunohistochemistry showed an IgG4/IgG ratio of more than 40% in the plasma cells in the inflammatory infiltrate, and he had an elevated serum IgG4 level. The lack of other organ involvement did not allow confirmation of an IgG4-RD. Previous treatments included topical corticosteroids, topical tacrolimus, intralesional corticosteroids, and hydroxychloroquine with no clinical improvement. Intralesional rituximab was initiated, and the lesions reduced in thickness after the third month. A marked decrease in tumor thickness and extension was found at month 6. High-resolution ultrasonography detected a decrease in tumor thickness and in vascularization on color Doppler mode. The patient underwent 10 infiltrations with CR and then treatment was stopped. In the following 4 months, the lesions mildly improved ( Figure 1B) . At month 12, the peripheral B-cell count was 3%. The patient was satisfied with the cosmetic result. The only observed adverse effects have been mild leukopenia and moderate pain during infiltrations.
Case 3
A man in his 50s presented with an 8-year history of a 14-cm violaceous plaque on his scalp (Figure 2A) . Several biopsies confirmed GF. Previous treatments included topical corticosteroids, topical tacrolimus, and hydroxychloroquine with no clinical improvement. Intralesional rituximab was initiated, with a significant reduction in size and thickness of the lesion after the third
Key Points
Question Is intralesional rituximab effective in the treatment of refractory granuloma faciale?
Findings In this case series of 3 patients with refractory granuloma faciale, treatment with 0.5 to 1 mL/cm 2 of intralesional rituximab (10 mg/mL) resulted in a complete response in 2 patients and a partial response in the third. A reduction in peripheral blood B-cell count was observed in the 3 patients, suggesting that the action of intralesional rituximab could be systemic; no severe adverse reactions were reported.
Meanings Intralesional rituximab may represent a novel and well-tolerated therapy in refractory granuloma faciale. infiltration. Ultrasonography confirmed these findings. Intralesional rituximab was stopped after the 10th infiltration owing to a CR, and no relapse was seen after 4 months of follow-up ( Figure 2B ). The peripheral B-cell count was 6% at baseline and 0 after 6 months of intralesional rituximab therapy. The patient was satisfied with the clinical outcome. No other alterations in blood analyses results were observed during therapy. The only observed adverse effect was moderate pain during infiltrations.
Discussion
Although most GF lesions are asymptomatic, they can induce severe cosmetic disfigurement. 1 Treatment is challenging, and the best approach for managing this disorder remains elusive. The pathogenesis of GF is not fully understood. Some studies have found perivascular deposition of complement and immunoglobulins, 1,7-9 suggesting vascular damage secondary to an immune complex-mediated mechanism. Cesinaro et al 2 reported that 22% of biopsies of GF fulfilled all immunohistochemical criteria for IgG4-RD, a fibroinflammatory condition mediated by IgG4 that manifests with masslike lesions and may affect 1 or more organs. However, these findings have not been confirmed by other studies. 10 Rituximab has been used successfully in different types of vasculitis, including urticaria vasculitis, 11 type II mixed cryoglobulinemia, 12 anti-neutrophil cytoplasmic antibodyassociated vasculitis, 13 and cutaneous small vessel vasculitis, 5, 14 as well as in several autoimmune dermatoses 4 and cutaneous IgG4-RD.
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All 3 patients treated with intralesional rituximab had a marked decrease in both size and thickness and were satisfied with the cosmetic outcome. Ultrasonography follow-up confirmed the decrease in GF thickness and vascularization. A reduction in peripheral blood B-cell count was observed in the patients at Research Brief Report Treatment of Refractory Granuloma Faciale With Intralesional Rituximab month 6, suggesting that the action of intralesional rituximab could be systemic. The exact mechanism of action of rituximab in GF is unknown. One possible explanation is that rituximab induces rapid depletion of circulating B-cells, which are precursors of autoantibody-secreting plasma cells and a source of immune complexes as observed in vasculitic disorders. However, rituximab also exerts an effect on diverse immune cells, including regulatory and effector T cells, and monocyte-derived macrophages. 4 
Strengths and Limitations
Rituximab is usually a well-tolerated therapy. 13, 15 No severe adverse reactions were observed in our patients with the exception of moderate pain associated with infiltrations. This treatment was not costly because of the low doses of rituximab required and the use of frozen remnants from treatment of other patients. The main limitations of this study are the small number of patients and lack of long-term follow-up.
Conclusions
We report 3 cases of refractory GF that were successfully treated with intralesional rituximab. The outcomes suggest that GF may be mediated by B cells. The satisfactory cosmetic results observed in our patients, together with its low cost and adequate safety profile, indicate that intralesional rituximab may be an alternative therapy in refractory GF. Larger studies with prolonged follow-up are needed to validate these preliminary findings. 
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